A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib
Qingxia Lin,1 Jinrong Zhu,2 Xuelei Gao3 1Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People’s Republic of China; 2Department of Central Pharmacy, Zhucheng People’s Hospital, Weifang, Shandong, People’s Republic of China; 3Department of Hepatopancr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-03-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-case-of-vitiligo-combined-with-systemic-lupus-erythematosus-treated--peer-reviewed-fulltext-article-CCID |
| _version_ | 1797253662999838720 |
|---|---|
| author | Lin Q Zhu J Gao X |
| author_facet | Lin Q Zhu J Gao X |
| author_sort | Lin Q |
| collection | DOAJ |
| description | Qingxia Lin,1 Jinrong Zhu,2 Xuelei Gao3 1Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People’s Republic of China; 2Department of Central Pharmacy, Zhucheng People’s Hospital, Weifang, Shandong, People’s Republic of China; 3Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People’s Republic of ChinaCorrespondence: Xuelei Gao, Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People’s Republic of China, Email gaoxuelei17@163.comAbstract: Vitiligo is a skin depigmentation disease resulting from melanocyte destruction and often co-occurring with autoimmune disorders like hyperthyroidism, alopecia areata, pernicious anemia, and systemic lupus erythematosus (SLE). Although various traditional treatments exist for vitiligo, their effectiveness varies considerably. This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions. These findings provide compelling evidence for the efficacy and safety of oral JAK inhibitors, such as tofacitinib, in vitiligo treatment. Additionally, JAK inhibitors can yet be regarded as a promising new treatment option for vitiligo patients with concurrent autoimmune diseases.Keywords: vitiligo, systemic lupus erythematosus, tofacitinib, JAK inhibitors |
| first_indexed | 2024-04-24T21:37:38Z |
| format | Article |
| id | doaj.art-b1e358b3602f46bc826af7ef9f0b4795 |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-04-24T21:37:38Z |
| publishDate | 2024-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-b1e358b3602f46bc826af7ef9f0b47952024-03-21T17:06:43ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152024-03-01Volume 1770771191392A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with TofacitinibLin QZhu JGao XQingxia Lin,1 Jinrong Zhu,2 Xuelei Gao3 1Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People’s Republic of China; 2Department of Central Pharmacy, Zhucheng People’s Hospital, Weifang, Shandong, People’s Republic of China; 3Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People’s Republic of ChinaCorrespondence: Xuelei Gao, Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People’s Republic of China, Email gaoxuelei17@163.comAbstract: Vitiligo is a skin depigmentation disease resulting from melanocyte destruction and often co-occurring with autoimmune disorders like hyperthyroidism, alopecia areata, pernicious anemia, and systemic lupus erythematosus (SLE). Although various traditional treatments exist for vitiligo, their effectiveness varies considerably. This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions. These findings provide compelling evidence for the efficacy and safety of oral JAK inhibitors, such as tofacitinib, in vitiligo treatment. Additionally, JAK inhibitors can yet be regarded as a promising new treatment option for vitiligo patients with concurrent autoimmune diseases.Keywords: vitiligo, systemic lupus erythematosus, tofacitinib, JAK inhibitorshttps://www.dovepress.com/a-case-of-vitiligo-combined-with-systemic-lupus-erythematosus-treated--peer-reviewed-fulltext-article-CCIDvitiligosystemic lupus erythematosustofacitinibjak inhibitors |
| spellingShingle | Lin Q Zhu J Gao X A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib Clinical, Cosmetic and Investigational Dermatology vitiligo systemic lupus erythematosus tofacitinib jak inhibitors |
| title | A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib |
| title_full | A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib |
| title_fullStr | A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib |
| title_full_unstemmed | A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib |
| title_short | A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib |
| title_sort | case of vitiligo combined with systemic lupus erythematosus treated with tofacitinib |
| topic | vitiligo systemic lupus erythematosus tofacitinib jak inhibitors |
| url | https://www.dovepress.com/a-case-of-vitiligo-combined-with-systemic-lupus-erythematosus-treated--peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT linq acaseofvitiligocombinedwithsystemiclupuserythematosustreatedwithtofacitinib AT zhuj acaseofvitiligocombinedwithsystemiclupuserythematosustreatedwithtofacitinib AT gaox acaseofvitiligocombinedwithsystemiclupuserythematosustreatedwithtofacitinib AT linq caseofvitiligocombinedwithsystemiclupuserythematosustreatedwithtofacitinib AT zhuj caseofvitiligocombinedwithsystemiclupuserythematosustreatedwithtofacitinib AT gaox caseofvitiligocombinedwithsystemiclupuserythematosustreatedwithtofacitinib |